Search

Displaying results 4511 - 4520 of 10000 in total
  1. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. … Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid
  2. Drug

    Kinetin

    go.drugbank.com/drugs/DB11336
    Approved

    Kinetin is a cytokinin which are plant hormones promotes cell division and plant growth. It was shown to naturally exist in DNA of organisms including humans and various plants. … While kinetin is used in tissue cultures to produce new plants, it is also found in cosmetic products as an anti-aging agents.

    Categories: Heterocyclic Compounds, 2-Ring
  3. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. … It is being pursued by Access Pharmaceuticals, Inc.

  4. Drug

    Oxolamine

    go.drugbank.com/drugs/DB13216
    Approved

    Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].

    Mixtures: KATARIN 120 MG+50 MG+1 MG/5 ML PEDIATRIK SURUP 100 ML, OLEDRO HOT D TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 6 ADETCategories: Heterocyclic Compounds, 1-Ring
  5. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    It is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  6. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. … Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.

  7. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid

  8. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  9. Drug

    Tromantadine

    go.drugbank.com/drugs/DB13288
    Approved

    Tromantadine is marketed as Viru-Merz in the Czech Republic [L5740]. It is an antiviral used in the treatment of herpes zoster and simplex.

  10. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors